First ALK2 Approval in FOP: Strong RCT Signal, Surrogate Endpoint Ceiling Ahead

FDA Approves ATEBRIOZ for Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals and Incyte announced that the U.S. FDA has approved ATEBRIOZ™ (zilurgisertib) tablets for adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). This once-daily oral activin receptor-like kinase 2 (ALK2) inhibitor is approved to reduce the volume of total new heterotopic ossification (HO). The approval was based on data from Cohort 1 of the PROGRESS study, where zilurgisertib-treated patients showed a mean decrease of 3.2 cm3 in total new HO lesion volume at Week 24, compared to an increase of 24.6 cm3 in placebo-treated patients. ATEBRIOZ is expected to be commercially available in the U.S. in October.

• The FDA's approval of ATEBRIOZ (zilurgisertib) marks a crucial advancement for adult and pediatric FOP patients aged 12 years and older, offering a new, once-daily oral treatment option for this devastating ultra-rare genetic disease. This milestone addresses a significant unmet medical need, reflecting successful collaboration between industry, researchers, and patient communities to bring forward an innovative therapy.
• Efficacy was established through Cohort 1 of the PROGRESS study, a Phase 2 trial. At Week 24, patients receiving zilurgisertib demonstrated a mean reduction of 3.2 cm3 in total new heterotopic ossification (HO) lesion volume, in stark contrast to a mean increase of 24.6 cm3 observed in placebo-treated patients. These positive treatment effects were sustained through Week 48 of the open-label extension period.
• ATEBRIOZ functions as a selective activin receptor-like kinase 2 (ALK2) inhibitor, directly targeting the disease-driving pathway in FOP where pathogenic ACVR1 gene variants lead to abnormal bone formation. Mirum Pharmaceuticals, which licensed zilurgisertib from Incyte, plans to make ATEBRIOZ commercially available in the U.S. in October, supported by the Mirum Access Plus (MAP) patient support program offering financial assistance.
• Beyond the initial approval, the PROGRESS pediatric development program is actively evaluating zilurgisertib in younger FOP patients, with enrollment completed for Cohort 2 (6 to <12 years) and underway for Cohort 3 (2 to <12 years). Additionally, a Marketing Authorization Application (MAA) for zilurgisertib is currently under review by the European Medicines Agency (EMA), indicating potential future availability in the European Union.

Addressing Unmet Needs in FOP Treatment

FOP presents a formidable therapeutic challenge: no treatment can completely prevent, halt, or reverse the progressive heterotopic ossification that defines the disease, and the only approved pharmacological option carries significant safety concerns. Current management strategies address symptoms rather than the underlying pathogenesis, leaving patients with limited and imperfect options.

• No definitive cure or disease-halting therapy exists. Despite surgical removal of HO being considered an effective intervention, it frequently results in recurrence and expansion of ossification. Surgical resection is also complicated by significant intraoperative hemorrhage and the difficulty of completely removing newly formed vasculature, and the International Clinical Council on FOP generally recommends avoiding surgery unless the situation is life-threatening, as soft tissue injury can trigger FOP flare-ups.

• Palovarotene, the only FDA-approved treatment, carries a high risk of serious adverse events. In the phase 3 MOVE trial, all palovarotene-treated patients reported at least one adverse event; 97.0% reported at least one retinoid-associated adverse event; and 29.3% reported at least one serious adverse event. Premature physeal closure or epiphyseal disorder occurred in 21 of 57 (36.8%) patients aged under 14 years. Post hoc computational analyses also showed decreased vertebral bone mineral density, content, and strength, and increased vertebral fracture risk in palovarotene-treated patients. Long-term safety and efficacy data for palovarotene are currently lacking.

• Existing non-pharmacological and conventional drug treatments target symptoms, not disease pathogenesis. Current clinical approaches — including NSAIDs, bisphosphonates, low-dose local radiation therapy, rehabilitation, and physical therapy — do not prevent the occurrence of HO and cannot address the fundamental mechanisms driving ossification.

• The complex and incompletely understood pathogenesis of HO in FOP impedes drug development. The continuous and complex process of HO in FOP is not yet fully understood, which has impeded the development of therapeutic drugs. While ACVR1/ALK2 mutations are the primary causative factor, the precise interplay of signaling pathways — including the role of Activin A as an obligate driver of HO — continues to be elucidated, complicating the identification and validation of therapeutic targets.

• Clinical trial design in this ultra-rare disease poses unique methodological challenges. The extremely limited patient population necessitates innovative trial designs, such as drug repositioning strategies and comparisons against natural history data rather than concurrent placebo controls, which introduces analytical complexity. The 12-month interim analyses of the MOVE trial met futility criteria, requiring post hoc analytical adjustments and independent Data Monitoring Committee review before trial continuation could be recommended.

PROGRESS Study: ATEBRIOZ Design and Efficacy in FOP

Three key studies have characterized the clinical development of palovarotene in fibrodysplasia ossificans progressiva (FOP), spanning a natural history study, a phase II program, and a phase III trial. Together, these investigations established imaging methodology, treatment regimens, and endpoints that define the current evidence base for HO reduction in this ultra-rare disorder.

A New Era for FOP Treatment: Oral ALK2 Inhibition Arrives

The FDA's green light for ATEBRIOZ™ (zilurgisertib) represents a pivotal moment for the FOP community, offering the first targeted oral therapy for a condition that has long lacked effective treatment options. FOP, characterized by debilitating heterotopic ossification, stems from gain-of-function mutations in the ALK2 receptor. Zilurgisertib's mechanism directly addresses this aberrant signaling, a significant scientific advancement from earlier, less targeted approaches.

Clinical data supporting the approval demonstrated a meaningful reduction in new HO volume, translating to a tangible benefit for patients facing progressive and cumulative bone formation in soft tissues. This approval not only provides hope but also validates the ALK2 inhibition pathway as a critical therapeutic target.

From a strategic perspective, this positions Mirum and Incyte at the forefront of FOP treatment. The drug's profile—a once-daily oral tablet that can be taken without regard to food, coupled with a half-life supporting convenient dosing—offers a significant advantage in patient adherence, especially for a rare disease population where treatment burden is a key consideration. Furthermore, the potential for non-invasive saliva-based drug monitoring could be particularly impactful for FOP patients, for whom traditional blood draws can be challenging and even risk-inducing.

However, the journey is not without its complexities. Clinicians will need to be mindful of potential drug-drug interactions, particularly with strong CYP3A4 inhibitors and inducers, which can significantly alter zilurgisertib exposure. The drug's non-linear pharmacokinetics also warrant careful consideration in dosing. Moreover, the FOP therapeutic landscape is dynamic, with other investigational therapies exploring different mechanisms, such as Activin A inhibition, suggesting that while zilurgisertib is a groundbreaking first, the competitive environment may evolve. Nevertheless, this approval marks a new era, shifting FOP management towards targeted, disease-modifying interventions.